PsiOxus oncolytic virus therapy heads towards clinic

A new oncolytic virus therapy that is intended to treat solid tumours is poised to enter clinical development triggering a $15 million milestone payment from Bristol-Myers Squibb Co to the developer PsiOxus Therapeutics Ltd of Oxford, UK.